Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Study Details
Study Description
Brief Summary
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
N/A |
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
Patients must have the following:
-
Diagnosis of AIDS with a case defining infection other than Mycobacterium avium complex (MAC).
-
Written informed consent obtained, which must include a statement that treatment may involve risks to the embryo or fetus, which are currently unforeseeable, if the subject becomes pregnant.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
-
Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine or didanosine (ddI).
-
Previous or current infection due to Mycobacterium avium complex (MAC) disease as evaluated by two successive blood cultures and two successive stool cultures taken within 14 days prior to study initiation.
Concurrent Medication:
Excluded:
-
Antiretroviral agents other than zidovudine (AZT).
-
Didanosine (ddI).
-
Antimycobacterial therapy.
-
Rifampin.
-
Isoniazid.
-
Clofazimine.
-
Ethambutol.
-
Cycloserine.
-
Ethionamide.
-
Amikacin.
-
Ciprofloxacin.
-
Streptomycin.
-
Other investigational drugs.
-
If antimicrobial therapy is required to treat bacterial infections (= or < 14 days), Adria Laboratories must be contacted prior to initiation of therapy.
Patients with the following are excluded:
-
Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine (AZT), or didanosine (ddI).
-
Previous or current Mycobacterium avium complex (MAC) infection.
-
Perceived patient unreliability or unavailability for frequent monitoring.
Prior Medication:
Excluded within 4 weeks of study entry:
-
Antiretroviral agents other than zidovudine (AZT) or didanosine (ddI).
-
Antimycobacterial therapy.
-
Rifampin.
-
Isoniazid.
-
Clofazimine.
-
Ethambutol.
-
Cycloserine.
-
Ethionamide.
-
Amikacin.
-
Ciprofloxacin.
Required:
-
Zidovudine (AZT).
-
Antipneumocystis prophylactic therapy.
Required for at least 4 weeks prior to study entry:
-
Zidovudine (AZT) or didanosine (ddI).
-
Antipneumocystis prophylaxis.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Maricopa County Med Ctr | Phoenix | Arizona | United States | 85010 |
2 | East Bay AIDS Ctr | Berkeley | California | United States | 94704 |
3 | Pacific Oaks Med Group | Beverly Hills | California | United States | 90211 |
4 | AIDS Community Research Consortium | Redwood City | California | United States | 94063 |
5 | HIV Research Group | San Diego | California | United States | 92102 |
6 | Dr Larry A Waites | San Francisco | California | United States | 94108 |
7 | Saint Francis Mem Hosp / HIV Care | San Francisco | California | United States | 94109 |
8 | Dr Marcus Conant | San Francisco | California | United States | 94115 |
9 | San Francisco Veterans Administration Med Ctr | San Francisco | California | United States | 94121 |
10 | Dr Marshall Kubota | Santa Rosa | California | United States | 95404 |
11 | Dr Jeffrey Galpin | Tarzana | California | United States | 91356 |
12 | Miami Veterans Administration Med Ctr | Miami | Florida | United States | 33125 |
13 | Community Research Initiative of South Florida | Miami | Florida | United States | 33137 |
14 | Northwestern Univ Med School | Chicago | Illinois | United States | 60611 |
15 | AIDS Research Alliance - Chicago | Chicago | Illinois | United States | 60657 |
16 | Tulane Univ School of Medicine | New Orleans | Louisiana | United States | 70112 |
17 | Comprehensive AIDS Alliance of Detroit / Harper Hosp | Detroit | Michigan | United States | 48201 |
18 | Univ of Minnesota | Minneapolis | Minnesota | United States | 55455 |
19 | St Paul Ramsey Med Ctr | St Paul | Minnesota | United States | 55101 |
20 | Univ of Nevada / Veterans Administration Med Ctr | Reno | Nevada | United States | 89520 |
21 | North Jersey Community Research Initiative | Newark | New Jersey | United States | 071032842 |
22 | Univ of New Mexico Hlth Sciences Ctr / Dept of Med | Albuquerque | New Mexico | United States | 87131 |
23 | Dr Donald Romig | Sante Fe | New Mexico | United States | 87501 |
24 | Albany Veterans Administration | Albany | New York | United States | 12208 |
25 | AIDS Services Erie County Med Ctr | Buffalo | New York | United States | 14215 |
26 | Community Health Network | Rochester | New York | United States | 14620 |
27 | Buckley Braffman Stern Med Associates | Philadelphia | Pennsylvania | United States | 19107 |
28 | Thomas Jefferson Med College | Philadelphia | Pennsylvania | United States | 19107 |
29 | Dr Alfred F Burnside Jr | Columbia | South Carolina | United States | 29204 |
30 | Infectious Disease Physicians Inc | Annandale | Virginia | United States | 22203 |
31 | Milwaukee County Med Complex | Milwaukee | Wisconsin | United States | 53226 |
32 | Univ of Calgary Health Science Ctr | Calgary | Alberta | Canada | |
33 | Univ of Alberta/Division of Inf Dis/Dept of Med | Edmonton | Alberta | Canada | |
34 | Saint Paul's Hosp | Vancouver | British Columbia | Canada | |
35 | Victoria Gen Hosp | Halifax | Nova Scotia | Canada | |
36 | McMaster Univ Med Ctr | Hamilton | Ontario | Canada | |
37 | Ottawa Gen Hosp | Ottawa | Ontario | Canada | |
38 | Mount Sinai Hosp | Toronto | Ontario | Canada | |
39 | Saint Michael's Hosp | Toronto | Ontario | Canada | |
40 | Sunnybrook Health Science Ctr | Toronto | Ontario | Canada | |
41 | Dr Emil Toma / Hotel Dieu de Montreal | Montreal | Quebec | Canada | |
42 | Montreal Chest Institute | Montreal | Quebec | Canada | |
43 | Montreal Gen Hosp | Montreal | Quebec | Canada |
Sponsors and Collaborators
- Pharmacia
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Dautzenberg B, Castellani P, Pellegrin JL, Vittecoq D, Truffot-Pernot C, Pirotta N, Sassella D. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother. 1996 Jul;40(7):1722-5.
- Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS. 1995 Dec;9(12):1337-42.
- 048B
- 087027-999